▶ 調査レポート

iPS細胞(人工多能性幹細胞)の世界市場

• 英文タイトル:Global Market Study on Induced Pluripotent Stem Cell: APEC to Present Lucrative Research Opportunities to Vendors in Future

Persistence Market Researchが調査・発行した産業分析レポートです。iPS細胞(人工多能性幹細胞)の世界市場 / Global Market Study on Induced Pluripotent Stem Cell: APEC to Present Lucrative Research Opportunities to Vendors in Future / B-PMR-JN006資料のイメージです。• レポートコード:B-PMR-JN006
• 出版社/出版日:Persistence Market Research / 2018年5月30日
• レポート形態:英文、PDF、271ページ
• 納品方法:Eメール(受注後2営業日)
• 産業分類:Life Sciences & Transformational Health
• 販売価格(消費税別)
  Individual(1名、印刷不可)¥519,400 (USD4,900)▷ お問い合わせ
  Multi User(5名)¥805,600 (USD7,600)▷ お問い合わせ
  Corporate User¥1,123,600 (USD10,600)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本資料は、iPS細胞(人工多能性幹細胞)の世界市場について調べ、iPS細胞(人工多能性幹細胞)の世界規模、市場動向、市場環境、細胞種類別(肝細胞、線維芽細胞、角化細胞、神経細胞、その他)分析、用途別(医薬品開発、毒性試験、再生医療、その他)分析、エンドユーザー別(学術機関・研究機関、バイオテクノロジー企業、その他)分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、関連企業情報などをまとめた調査レポートです。
・エグゼクティブサマリー
・調査手法
・iPS細胞(人工多能性幹細胞)の世界市場環境
・iPS細胞(人工多能性幹細胞)の世界市場動向
・iPS細胞(人工多能性幹細胞)の世界市場規模
・iPS細胞(人工多能性幹細胞)の世界市場規模:細胞種類別(肝細胞、線維芽細胞、角化細胞、神経細胞、その他)
・iPS細胞(人工多能性幹細胞)の世界市場規模:用途別(医薬品開発、毒性試験、再生医療、その他)
・iPS細胞(人工多能性幹細胞)の世界市場規模:エンドユーザー別(学術機関・研究機関、バイオテクノロジー企業、その他)
・iPS細胞(人工多能性幹細胞)の世界市場:地域別市場規模・分析
・iPS細胞(人工多能性幹細胞)の北米市場規模・予測
・iPS細胞(人工多能性幹細胞)のアメリカ市場規模・予測
・iPS細胞(人工多能性幹細胞)のヨーロッパ市場規模・予測
・iPS細胞(人工多能性幹細胞)のアジア市場規模・予測
・iPS細胞(人工多能性幹細胞)の日本市場規模・予測
・iPS細胞(人工多能性幹細胞)の中国市場規模・予測
・iPS細胞(人工多能性幹細胞)のインド市場規模・予測
・関連企業情報・競争状況

Overview of the iPS Cell Market with Reference to the Global Healthcare Sector Outlook

Despite the economic and political uncertainty in the recent past, the global healthcare industry has been receiving positive nudges from reformative and technological disruptions in medical devices, pharmaceuticals and biotech, in-vitro diagnostics, and medical imaging. Key markets across the world are facing a massive rise in demand for critical care services that are pushing global healthcare spending levels to unimaginable limits.

A rapidly multiplying geriatric population; increasing prevalence of chronic ailments such as cancer and cardiac disease; growing awareness among patients; and heavy investments in clinical innovation are just some of the factors that are impacting the performance of the global healthcare industry. Proactive measures such as healthcare cost containment, primary care delivery, innovation in medical procedures (3-D printing, blockchain, and robotic surgery to name a few), safe and effective drug delivery, and well-defined healthcare regulatory compliance models are targeted at placing the sector on a high growth trajectory across key regional markets.

Parent Indicators Healthcare

Current expenditure on health, % of gross domestic product
Current expenditure on health, per capita, US$ purchasing power parities (current prices, current PPPs)
Annual growth rate of current expenditure on health, per capita, in real terms
Out-of-pocket expenditure, % of current expenditure on health
Out-of-pocket expenditure, per capita, US$ purchasing power parity (current prices, current PPPs)
Physicians, Density per 1000 population (head counts)
Nurses, Density per 1000 population (head counts)
Total hospital beds, per 1000 population
Curative (acute) care beds, per 1000 population
Medical technology, Magnetic Resonance Imaging units, total, per million population
Medical technology, Computed Tomography scanners, total, per million population
Research Methodology

PMR utilizes a triangulation methodology that is primarily based on overall expenditure on life science research and R&D funding and capital equipment installed base to obtain precise market estimations and insights on life science and biotechnology associated products, technologies, applications and services. Bottom-up approach is always used to obtain insightful data for the specific country/regions. The country-specific data is again analysed to derive data at a global level. This methodology ensures high quality and accuracy of information.

Secondary research is used at the initial phase to identify the feasibility of the target products/technology categories and its respective segments, product and service offerings, equipment installed base in end use facilities, adoption rate and future impact of new technologies. Additionally, per capita consumption of kits, reagents and consumables among end users is tracked at a granular level to obtain the most accurate information. Each piece of information is eventually analysed during the entire research project which builds a strong base for the primary research information.

Primary research participants include demand-side respondents such as laboratory managers, procurement managers, research supervisors at academic and research institutes, as well as key opinion leaders in addition to supply-side respondents such as equipment and reagent manufacturers, custom solution and service providers who provide valuable insights on trends, research application of products and technologies, purchasing patterns, services offered and associated pricing.

Quantitative and qualitative assessment of basic factors driving demand, economic factors/cycles and growth rates and strategies utilized by key players in the market is analysed in detail while forecasting, in order to project year-on-year growth rates. These Y-o-Y growth projections are checked and aligned as per associated industry/product lifecycles and further utilized to develop market numbers at a holistic level.

On the other hand, we also analyse annual reports of various companies, investor presentations, SEC filings, 10k reports and earning call transcripts operating in the market to fetch substantial information about the market size, trends, opportunity, drivers, restraints and to analyse key players and their market shares. Key companies are segmented at tier-level based on their revenues, product portfolio and presence.

Please note that these are the partial steps that are being followed while developing the market size. Besides this, forecasting will be done based on our internal proprietary model which also uses different macro-economic factors such as overall life science research expenditure, R&D funding, industry based demand driving factors impacting the market and its forecast trends apart from other macroeconomic factors.

Standard Report Structure

Executive Summary
Market Definition
Macro-economic analysis
Parent Market Analysis
Market Overview
Forecast Factors
Segmental Analysis and Forecast
Regional Analysis
Competition Analysis
Market Taxonomy

The global iPS cell market has been segmented into:

Cell Type

Hepatocytes
Fibroblasts
Keratinocytes
Neurons
Others
Application

Drug Development
Regenerative Medicine
Toxicity Testing
End User

Academic and Research Institutes
Biotechnology Companies
Region

North America
Latin America
Europe
Asia Pacific excluding China (APEC)
China
Middle East and Africa (MEA)

レポート目次

1. Executive Summary
1.1. Market Overview
1.2. Market Analysis
1.3. PMR Analysis and Recommendations
1.4. Wheel of Fortune

2. Market Introduction
2.1. Market Definition
2.2. Market Taxonomy

3. Induced Pluripotent Stem cells Market Opportunity Analysis
3.1. Macro-Economic Factors
3.2. Opportunity Analysis

4. Market Background
4.1. Parent Market Overview
4.2. Induced Pluripotent Stem Cell Timeline
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Trends

5. Macroeconomic Assumptions

6. Global Economic Outlook
6.1. Gross Domestic Product by Region & Country, 2006 – 2021
6.2. Healthcare Indicators

7. Key Inclusions
7.1. Usage Trend in Industry
7.2. Active Researchers in Stem Cell Research
7.3. Induced Pluripotent Stem Cell Therapy for Cardiovascular Disease
7.4. In-Vivo Modelling for Neurological Disorder Using Induced Pluripotent Stem Cells
7.5. Pipeline Assessment

8. North America Induced Pluripotent Stem Cells Market Analysis 2013–2017 and Forecast 2018–2026
8.1. Introduction
8.2. Regional Market Trends
8.3. Historical Market Size (US$ Mn) Trend Analysis By Country, 2013–2017
8.3.1. U.S.
8.3.2. Canada
8.4. Market Size (US$ Mn) Forecast By Country, 2018–2026
8.5. Historical Market Size (US$ Mn) Trend Analysis By Cell Type, 2013–2017
8.5.1. Hepatocytes
8.5.2. Fibroblasts
8.5.3. Keratinocytes
8.5.4. Neurons
8.5.5. Others
8.6. Market Size (US$ Mn) Forecast By Cell Type, 2018–2026
8.7. Historical Market Size (US$ Mn) Trend Analysis By Application, 2013–2017
8.7.1. Drug Development
8.7.2. Toxicity testing
8.7.3. Regenerative Medicine
8.7.4. Others
8.8. Market Size (US$ Mn) Forecast By Application, 2018–2026
8.9. Historical Market Size (US$ Mn) Trend Analysis By End User, 2013–2017
8.9.1. Academic & Research Institutes
8.9.2. Biotechnology companies
8.9.3. Others
8.10. Market Size (US$ Mn) Forecast By End User, 2018–2026
8.11. Drivers and Restraints: Impact Analysis
8.12. Market Attractiveness Analysis
8.12.1. By Country
8.12.2. By Cell Type
8.12.3. By Application
8.12.4. By End User
8.13. Key Market Participants – Intensity Mapping
8.14. Drivers and Restraints – Impact Analysis

9. Latin America Induced Pluripotent Stem Cells Market Analysis 2013–2017 and Forecast 2018–2026
9.1. Introduction
9.2. Regional Market Trends
9.3. Historical Market Size (US$ Mn) Trend Analysis By Country, 2013–2017
9.3.1. Argentina
9.3.2. Brazil
9.3.3. Mexico
9.3.4. Rest of Latin America
9.4. Market Size (US$ Mn) Forecast By Country, 2018–2026
9.5. Historical Market Size (US$ Mn) Trend Analysis By Cell Type, 2013–2017
9.5.1. Hepatocytes
9.5.2. Fibroblasts
9.5.3. Keratinocytes
9.5.4. Neurons
9.5.5. Others
9.6. Market Size (US$ Mn) Forecast By Cell Type, 2018–2026
9.7. Historical Market Size (US$ Mn) Trend Analysis By Application, 2013–2017
9.7.1. Drug Development
9.7.2. Toxicity testing
9.7.3. Regenerative Medicine
9.7.4. Others
9.8. Market Size (US$ Mn) Forecast By Application, 2018–2026
9.9. Historical Market Size (US$ Mn) Trend Analysis By End User, 2013–2017
9.9.1. Academic & Research Institutes
9.9.2. Biotechnology companies
9.9.3. Others
9.10. Market Size (US$ Mn) Forecast By End User, 2018–2026
9.11. Drivers and Restraints: Impact Analysis
9.12. Market Attractiveness Analysis
9.12.1. By Country
9.12.2. By Cell Type
9.12.3. By Application
9.12.4. By End User
9.13. Key Market Participants – Intensity Mapping
9.14. Drivers and Restraints – Impact Analysis
9.15. Key Mergers & Acquisitions

10. Europe Induced Pluripotent Stem Cells Market Analysis 2013–2017 and Forecast 2018–2026
10.1. Introduction
10.2. Regional Market Trends
10.3. Historical Market Size (US$ Mn) Trend Analysis By Country, 2013–2017
10.3.1. Germany
10.3.2. U.K.
10.3.3. France
10.3.4. Italy
10.3.5. Spain
10.3.6. Russia
10.3.7. Rest of Europe
10.4. Market Size (US$ Mn) Forecast By Country, 2018–2026
10.5. Historical Market Size (US$ Mn) Trend Analysis By Cell Type, 2013–2017
10.5.1. Hepatocytes
10.5.2. Fibroblasts
10.5.3. Keratinocytes
10.5.4. Neurons
10.5.5. Others
10.6. Market Size (US$ Mn) Forecast By Cell Type, 2018–2026
10.7. Historical Market Size (US$ Mn) Trend Analysis By Application, 2013–2017
10.7.1. Drug Development
10.7.2. Toxicity testing
10.7.3. Regenerative Medicine
10.7.4. Others
10.8. Market Size (US$ Mn) Forecast By Application, 2018–2026
10.9. Historical Market Size (US$ Mn) Trend Analysis By End User, 2013–2017
10.9.1. Academic & Research Institutes
10.9.2. Biotechnology companies
10.9.3. Others
10.10. Market Size (US$ Mn) Forecast By End User, 2018–2026
10.11. Drivers and Restraints: Impact Analysis
10.12.Market Attractiveness Analysis
10.12.1. By Country
10.12.2. By Cell Type
10.12.3. By Application
10.12.4. By End User
10.13. Key Market Participants – Intensity Mapping
10.14. Drivers and Restraints – Impact Analysis
10.15. Key Mergers & Acquisitions

11. Asia Pacific Induced Pluripotent Stem Cells Market Analysis 2013–2017 and Forecast 2018–2026
11.1. Introduction
11.2. Regional Market Trends
11.3. Historical Market Size (US$ Mn) Trend Analysis By Country, 2013–2017
11.3.1. Japan
11.3.2. India
11.3.3. Australia and New Zealand
11.3.4. Rest of Asia Pacific
11.4. Market Size (US$ Mn) Forecast By Country, 2018–2026
11.5. Historical Market Size (US$ Mn) Trend Analysis By Cell Type, 2013–2017
11.5.1. Hepatocytes
11.5.2. Fibroblasts
11.5.3. Keratinocytes
11.5.4. Neurons
11.5.5. Others
11.6. Market Size (US$ Mn) Forecast By Cell Type, 2018–2026
11.7. Historical Market Size (US$ Mn) Trend Analysis By Application, 2013–2017
11.7.1. Drug Development
11.7.2. Toxicity testing
11.7.3. Regenerative Medicine
11.7.4. Others
11.8. Market Size (US$ Mn) Forecast By Application, 2018–2026
11.9. Historical Market Size (US$ Mn) Trend Analysis By End User, 2013–2017
11.9.1. Academic & Research Institutes
11.9.2. Biotechnology companies
11.9.3. Others
11.10. Market Size (US$ Mn) Forecast By End User, 2018–2026
11.11. Drivers and Restraints: Impact Analysis
11.12. Market Attractiveness Analysis
11.12.1. By Country
11.12.2. By Cell Type
11.12.3. By Application
11.12.4. By End User
11.13. Key Market Participants – Intensity Mapping
11.14. Drivers and Restraints – Impact Analysis
11.15. Key Mergers & Acquisitions

12. China Induced Pluripotent Stem Cells Market Analysis 2013–2017 and Forecast 2018–2026
12.1. Introduction
12.2. Key Regulations
12.3. Historical Market Size (US$ Mn) Trend Analysis By Cell Type, 2013–2017
12.3.1. Hepatocytes
12.3.2. Fibroblasts
12.3.3. Keratinocytes
12.3.4. Neurons
12.3.5. Others
12.4. Market Size (US$ Mn) Forecast By Cell Type, 2018–2026
12.5. Historical Market Size (US$ Mn) Trend Analysis By Application, 2013–2017
12.5.1. Drug Development
12.5.2. Toxicity testing
12.5.3. Regenerative Medicine
12.5.4. Others
12.6. Market Size (US$ Mn) Forecast By Application, 2018–2026
12.7. Historical Market Size (US$ Mn) Trend Analysis By End User, 2013–2017
12.7.1. Academic & Research Institutes
12.7.2. Biotechnology companies
12.7.3. Others
12.8. Market Size (US$ Mn) Forecast By End User, 2018–2026
12.9. Drivers and Restraints: Impact Analysis
12.10. Market Attractiveness Analysis
12.10.1. By Cell Type
12.10.2. By Application
12.10.3. By End User
12.11. Key Market Participants – Intensity Mapping
12.12. Drivers and Restraints – Impact Analysis
12.13. Key Mergers & Acquisitions

13. Middle East & Africa Induced Pluripotent Stem Cells Market Analysis 2013–2017 and Forecast 2018–2026
13.1. Introduction
13.2. Key Regulations
13.3. Historical Market Size (US$ Mn) Trend Analysis By Country, 2013–2017
13.3.1. GCC Countries
13.3.2. South Africa
13.3.3. Rest of MEA
13.4. Market Size (US$ Mn) Forecast By Country, 2018–2026
13.5. Historical Market Size (US$ Mn) Trend Analysis By Cell Type, 2013–2017
13.5.1. Hepatocytes
13.5.2. Fibroblasts
13.5.3. Keratinocytes
13.5.4. Neurons
13.5.5. Others
13.6. Market Size (US$ Mn) Forecast By Cell Type, 2018–2026
13.7. Historical Market Size (US$ Mn) Trend Analysis By Application, 2013–2017
13.7.1. Drug Development
13.7.2. Toxicity testing
13.7.3. Regenerative Medicine
13.7.4. Others
13.8. Market Size (US$ Mn) Forecast By Application, 2018–2026
13.9. Historical Market Size (US$ Mn) Trend Analysis By End User, 2013–2017
13.9.1. Academic & Research Institutes
13.9.2. Biotechnology companies
13.9.3. Others
13.10. Market Size (US$ Mn) Forecast By End User, 2018–2026
13.11. Drivers and Restraints: Impact Analysis
13.12. Market Attractiveness Analysis
13.12.1. By Country
13.12.2. By Cell Type
13.12.3. By Application
13.12.4. By End User
13.13. Key Market Participants – Intensity Mapping
13.14. Drivers and Restraints – Impact Analysis
13.15. Key Mergers & Acquisitions

14. Forecast Factors: Relevance and Impact

15. Forecast Assumptions

16. Market Structure Analysis
16.1. Market Structure by Tier of Companies
16.2. Market Share Analysis (2016) for Top Players, By Region

17. Competition Analysis
17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Company Deep Dive
17.3.1. Thermo Fisher Scientific Inc.
17.3.1.1. Overview
17.3.1.2. Product and Application Portfolio
17.3.1.3. Production Footprint
17.3.1.4. Sales Footprint
17.3.1.5. Channel Footprint
17.3.1.6. Strategy
17.3.1.6.1. Marketing Strategy
17.3.1.6.2. Product Strategy
17.3.1.6.3. Channel Strategy
17.3.2. FUJIFILM Holdings Corporation (Cellular Dynamics)
17.3.2.1. Overview
17.3.2.2. Product and Application Portfolio
17.3.2.3. Production Footprint
17.3.2.4. Sales Footprint
17.3.2.5. Channel Footprint
17.3.2.6. Strategy
17.3.2.6.1. Marketing Strategy
17.3.2.6.2. Product Strategy
17.3.2.6.3. Channel Strategy
17.3.3. Horizon Discovery Group plc.
17.3.3.1. Overview
17.3.3.2. Product and Application Portfolio
17.3.3.3. Production Footprint
17.3.3.4. Sales Footprint
17.3.3.5. Channel Footprint
17.3.3.6. Strategy
17.3.3.6.1. Marketing Strategy
17.3.3.6.2. Product Strategy
17.3.3.6.3. Channel Strategy
17.3.4. Takara Bio Inc.
17.3.4.1. Overview
17.3.4.2. Product and Application Portfolio
17.3.4.3. Production Footprint
17.3.4.4. Sales Footprint
17.3.4.5. Channel Footprint
17.3.4.6. Strategy
17.3.4.6.1. Marketing Strategy
17.3.4.6.2. Product Strategy
17.3.4.6.3. Channel Strategy
17.3.5. Cell Applications, Inc.
17.3.5.1. Overview
17.3.5.2. Product and Application Portfolio
17.3.5.3. Production Footprint
17.3.5.4. Sales Footprint
17.3.5.5. Channel Footprint
17.3.5.6. Strategy
17.3.5.6.1. Marketing Strategy
17.3.5.6.2. Product Strategy
17.3.5.6.3. Channel Strategy
17.3.6. Lonza Group Ltd.
17.3.6.1. Overview
17.3.6.2. Product and Application Portfolio
17.3.6.3. Production Footprint
17.3.6.4. Sales Footprint
17.3.6.5. Channel Footprint
17.3.6.6. Strategy
17.3.6.6.1. Marketing Strategy
17.3.6.6.2. Product Strategy
17.3.6.6.3. Channel Strategy

18. Global Induced Pluripotent Stem Cells Market Analysis 2013–2017 and Forecast 2018–2026, By Region
18.1. Introduction/Key Findings
18.2. Historical Market Size (US$ Mn) Trend Analysis By Region, 2013–2017
18.3. Market Size (US$ Mn) Forecast By Region, 2018–2026
18.3.1. North America
18.3.2. Latin America
18.3.3. Europe
18.3.4. Asia Pacific
18.3.5. Middle East & Africa
18.3.6. China
18.4. Market Attractiveness Analysis By Region

19. Global Induced Pluripotent Stem Cells Analysis 2013–2017 and Forecast 2018–2026, By Cell Type
19.1. Introduction/Key Findings
19.2. Historical Market Size (US$ Mn) Trend Analysis By Cell Type, 2013–2017
19.2.1. Hepatocytes
19.2.2. Fibroblasts
19.2.3. Keratinocytes
19.2.4. Neurons
19.2.5. Others
19.3. Market Size (US$ Mn) Forecast By Cell Type, 2018–2026
19.4. Market Attractiveness Analysis By Cell Type

20. Global Induced Pluripotent Stem Cells Market Analysis 2013–2017 and Forecast 2018–2026, By Application
20.1. Introduction/Key Findings
20.2. Historical Market Size (US$ Mn) Trend Analysis By Application, 2013–2017
20.2.1. Drug Development
20.2.2. Toxicity testing
20.2.3. Regenerative Medicine
20.2.4. Others
20.3. Market Size (US$ Mn) Forecast By Application, 2018–2026
20.4. Market Attractiveness Analysis By Application

21. Global Induced Pluripotent Stem Cells Market Analysis 2013–2017 and Forecast 2018–2026, By End User
21.1. Introduction/Key Findings
21.2. Historical Market Size (US$ Mn) Trend Analysis By End User, 2013–2017
21.2.1. Academic & Research Institutes
21.2.2. Biotechnology companies
21.2.3. Others
21.3. Market Size (US$ Mn) Forecast By End User, 2018–2026
21.4. Market Attractiveness Analysis By End User

22. Global Induced Pluripotent Stem Cells Market Analysis 2013–2017 and Forecast 2018–2026
22.1. Market Value Share Analysis By All Segment
22.2. Y-o-Y Growth Analysis By All Segment
22.3. Absolute $ Opportunity

23. Assumptions and Acronyms

24. Research Methodology

List of Tables

Table 01: Comparison of Stem Cell Types
Table 02: Expenditure on Health, (% of GDP), by Country, 2016 - 2021
Table 03: Expenditure on Health, (% of GDP), by Country, 2016 - 2021
Table 04: Induced Pluripotent Stem Cells (iPSCs) Clinical Trials
Table 05: Induced Pluripotent Stem Cells (iPSCs) Clinical Trials
Table 06: Induced Pluripotent Stem Cells (iPSCs) Clinical Trials
Table 07: Induced Pluripotent Stem Cells (iPSCs) Clinical Trials
Table 08: Induced Pluripotent Stem Cells (iPSCs) Clinical Trials
Table 09: Induced Pluripotent Stem Cells (iPSCs) Clinical Trials
Table 10: Induced Pluripotent Stem Cells (iPSCs) Clinical Trials
Table 11: North America Induced Pluripotent Stem Cell Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Country
Table 12: North America Induced Pluripotent Stem Cell Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Cell Type
Table 13: North America Induced Pluripotent Stem Cell Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Application Type
Table 14: North America Induced Pluripotent Stem Cell Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By End User
Table 15: North America Induced Pluripotent Stem Cell Market Company Intensity Map
Table 16: Economic support and stem cell research for the major countries in Latin America, (2013)
Table 17: Latin America Induced Pluripotent Stem Cell Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Country
Table 18: Latin America Induced Pluripotent Stem Cell Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Cell Type
Table 19: Latin America Induced Pluripotent Stem Cell Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Application Type
Table 20: Latin America Induced Pluripotent Stem Cell Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By End User
Table 21: Latin America Induced Pluripotent Stem Cell Market Company Intensity Map
Table 22: Europe Induced Pluripotent Stem Cell Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Country
Table 23: Europe Induced Pluripotent Stem Cell Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Cell Type
Table 24: Europe Induced Pluripotent Stem Cell Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Application Type
Table 25: Europe Induced Pluripotent Stem Cell Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By End User
Table 26: Europe Induced Pluripotent Stem Cell Market Company Intensity Map
Table 28: Asia Pacific excluding China (APEC) Induced Pluripotent Stem Cell Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Country
Table 29: Asia Pacific excluding China (APEC) Induced Pluripotent Stem Cell Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Cell Type
Table 30: Asia Pacific excluding China (APEC) Induced Pluripotent Stem Cell Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Application Type
Table 31: Asia Pacific excluding China (APEC) Induced Pluripotent Stem Cell Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By End User
Table 32: Asia Pacific excluding China (APEC) Induced Pluripotent Stem Cell Market Company Intensity Map
Table 33: China Induced Pluripotent Stem Cell Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Cell Type
Table 34: China Induced Pluripotent Stem Cell Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Application Type
Table 35: China Induced Pluripotent Stem Cell Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By End User
Table 36: China Induced Pluripotent Stem Cell Market Company Intensity Map
Table 37: Middle East and Africa (MEA) Induced Pluripotent Stem Cell Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Country
Table 38: Middle East and Africa (MEA) Induced Pluripotent Stem Cell Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Cell Type
Table 39: Middle East and Africa (MEA) Induced Pluripotent Stem Cell Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Application Type
Table 40: Middle East and Africa (MEA) Induced Pluripotent Stem Cell Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By End User
Table 41: Middle East and Africa (MEA) Induced Pluripotent Stem Cell Market Company Intensity Map
Table 42: Global Induced Pluripotent Stem Cell Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Region
Table 43: Global Induced Pluripotent Stem Cell Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Cell Type
Table 44: Global Induced Pluripotent Stem Cell Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Application Type
Table 45: Global Induced Pluripotent Stem Cell Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By End User